Inactive Instrument

Other languages Incannex Healthcare Australian S.E.

Equities

Incannex Healthcare Inc. Announces Executive Changes	Mar. 05
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	Feb. 28
Incannex Healthcare Completes Pre-Investigational New Drug Meeting on CannQuit-N With US FDA	Feb. 16
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N	Feb. 16
Incannex Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	Jan. 24
Incannex Completes Dosing and Therapy in Phase 2 ?Psigad? Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder	Jan. 18
Incannex Healthcare Gets Institutional Review Board Approval For IHL-42X Drug Trial	Jan. 17
Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	Jan. 17
Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia	Dec. 21
Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea	Dec. 06
Incannex Healthcare Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30
Incannex Healthcare Inc. Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-26

No results for this search